Economic evaluation of sirolimus-eluting stents

CMAJ. Canadian Medical Association Journal

Volumn 172, Issue 3, 2005, Pages 345-351

  Shrive, Fiona M ^a,b   Manns, Braden J ^a,b   Galbraith, P Diane ^a,b   Knudtson, Merril L ^a,b   Ghali, William A ^a,b,c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN;

ARTICLE; COHORT ANALYSIS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG ELUTING STENT; EVALUATION; HEALTH CARE COST; HEALTH ECONOMICS; HEART CATHETERIZATION; HIGH RISK PATIENT; PATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; QUALITY ADJUSTED LIFE YEAR; RESTENOSIS; REVASCULARIZATION;

EID: 13444252632     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: 10.1503/cmaj.1041062     Document Type: Article

References (22)

1. Cutlip DE, Chauhan MS, Baim DS, Ho KKL, Popma JJ, Carrozza JP, et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol 2002;40:2082-9.
2. Weaver WD, Reisman MA, Griffin JJ, Buller CE, Leimgruber PP, Henry T. Optimum percutaneous transluminal coronary angioplasty compared with routine stent strategy trial (OPUS-1): a randomised trial. Lancet 2000;355: 2199-203.
3. Jamal SM, Shrive FM, Ghali WA, Knudtson ML, Eisenberg MJ, for the Canadian Cardiovascular Outcomes Research Team (CCORT). In-hospital outcomes after percutaneous coronary intervention in Canada: 1992/93 to 2000/01. Can J Cardiol 2003;19:782-9.
4. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.
5. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
6. Schampaert E, Cohen EA, Schluter M, Reeves F, Traboulsi M, Title LM, et al, for the C-SIRIUS Investigators. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004;43:1110-5.
7. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, et al; E-SIRIUS investigators. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362:1093-9.
8. Reimbursement and coding guidelines for drug-eluting stents. Johnson & Johnson-Cordis Corporation; 2003. Available: www.cordis.com/active/crdus /en_US/html/cordis/downloads/DES_guide.pdf (accessed 2004 Nov 24).
9. Ghali WA, Knudtson ML, on behalf of the APPROACH investigators. Overview of the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease. Can J Cardiol 2000;16:1225-30.
10. Norris CM, Ghali WA, Knudtson ML, Saunders LD, Naylor CD. Dealing with missing data in observational health care outcome analysis. J Clin Epidemiol 2000;53:377-83.
11. Annual demographic statistics. Ottawa: Statistics Canada; cat no 91-213-XIB.
12. Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic evaluations of pharmaceuticals. 2nd ed. Ottawa: CCOHTA; 1997. p. 4.
13. Consumer price index, July 2004. The Daily [Statistics Canada];2004 Aug 24. Available; www.statcan.ca/Daily/English/040824/d040824a.htm (accessed 2004 Dec 9).
14. Goodney PP, O'Connor GT, Wennberg DE, Birkmeyer JD. Do hospitals with low mortality rates in coronary artery bypass also perform well in valve replacement? Ann Thorac Surg 2003;76:1131-7.
15. Malenka DJ, Wennberg DE, Quinton HA, O'Rourke DJ, McGrath PD, Shubrooks SJ, et al, for the Northern New England Cardiovascular Disease Study Group. Gender-related changes in practice and outcomes of percutaneous coronary interventions in northern New England from 1994 to 1999. J Am Coll Cardiol 2002;40:2092-101.
16. Greenberg D, Bakhai A, Cohen DJ. Can we afford to eliminate restenosis? Can we afford not to? J Am Coll Cardiol 2004;43:513-8.
17. The CEA registry: standardizing the methods and practices of cost-effectiveness analysis [Web site of Harvard Center for Risk Analysis, Harvard School of Public Health, Boston], Available: www.hsph.Harvard.edu/ cearegistry (accessed 2004 Nov 24).
18. Pliskin JS, Stason WB, Weinstein MC, Johnson RA, Cohn PF, McEnany MT, et al. Coronary artery bypass graft surgery: clinical decision making and cost-effectiveness analysis. Med Decis Making 1981;1(1)10-28.
19. Weinstein MC, Stason WB. Cost-effectiveness of coronary-artery bypass surgery. Circulation 1982;66(3 Suppl):III56-III66.
20. Owens DK, Sanders GD, Harris RA, McDonald KM, Heidenreich PA, Dembitzer AD, et al. Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death. Ann Intern Med 1997;126:1-12.
21. CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 2002;287:2542-51.
22. Giedd KN, Bergmann SR. Myocardial perfusion imaging following percutaneous coronary intervention: the importance of restenosis, disease progression, and directed reintervention. J Am Coll Cardiol 2004;43:328-36.